Base de dados : MEDLINE
Pesquisa : D20.215 [Categoria DeCS]
Referências encontradas : 16771 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1678 ir para página                         

  1 / 16771 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29231144
[Au] Autor:Castellano G; Redondo L; Torrens F
[Ad] Endereço:Departamento de Ciencias Experimentales y Matematicas, Facultad de Veterinaria y Ciencias Experimentales, Universidad Catolica de Valencia San Vicente Martir, Guillem de Castro-94, E-46001 Valencia, Spain.
[Ti] Título:QSAR of Natural Sesquiterpene Lactones as Inhibitors of Myb-dependent Gene Expression.
[So] Source:Curr Top Med Chem;17(30):3256-3268, 2018 Feb 09.
[Is] ISSN:1873-4294
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Protein c-Myb is a therapeutic target. Some sesquiterpene lactones suppress Myb-dependent gene expression, which results in their potential anti-cancer activity. MATERIAL & METHODS: Database ChEMBL is a representative of lactones for physicochemical and physiochemical properties. Data presented for 31 natural lactones are discussed in terms of quantitative structureactivity relationships with the objective to predict inhibitors of Myb-induced gene expression. Several constitutional descriptors are related to structure-activity. α-Methylene-γ-lactone groups enhance while OH functions worsen potency. The latter feature is in agreement with the fact that the more lipophilic the lactone, the greater the cytotoxicity because of the ability to cross lipoidal biomembranes. In general, numbers of π-systems and atoms, and polarizability enhance activity. Linear and nonlinear structure-activity models are developed, between lactones of a great structural diversity, to predict inhibitors of Myb-induced gene expression. Four variables (ML, UNC, TCO+OCOR, UNC+UNA) related to ATOM show a positive correlation because of the partial anionic and H-acceptor characters of O-atom. In most, CO group is conjugated. RESULT AND CONCLUSION: Term OH shows negative coefficients because of the partial cationic quality of H-atom and because OH forms H-bonds with CO, causing them to be less H-acceptor. s-trans-s-trans-Germacranolide structure is the most active. Coefficients standard errors result acceptable in almost all equations. After cross-validation, linear equations for lactones, pseudoguaianolides and germacranolides are the most predictive. Most descriptors are constitutional variables.
[Mh] Termos MeSH primário: Produtos Biológicos/farmacologia
Regulação da Expressão Gênica/efeitos dos fármacos
Lactonas/farmacologia
Proteínas Proto-Oncogênicas c-myb/antagonistas & inibidores
Relação Quantitativa Estrutura-Atividade
Sesquiterpenos/farmacologia
[Mh] Termos MeSH secundário: Produtos Biológicos/química
Relação Dose-Resposta a Droga
Seres Humanos
Lactonas/química
Modelos Moleculares
Estrutura Molecular
Proteínas Proto-Oncogênicas c-myb/genética
Sesquiterpenos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Lactones); 0 (Proto-Oncogene Proteins c-myb); 0 (Sesquiterpenes)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.2174/1568026618666171211145846


  2 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29358154
[Au] Autor:Turner AD; Waack J; Lewis A; Edwards C; Lawton L
[Ad] Endereço:Centre for Environment, Fisheries and Aquaculture Science, Barrack Road, The Nothe, Weymouth, Dorset DT4 8UB, United Kingdom. Electronic address: andrew.turner@cefas.co.uk.
[Ti] Título:Development and single-laboratory validation of a UHPLC-MS/MS method for quantitation of microcystins and nodularin in natural water, cyanobacteria, shellfish and algal supplement tablet powders.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1074-1075:111-123, 2018 Feb 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A simple, rapid UHPLC-MS/MS method has been developed and optimised for the quantitation of microcystins and nodularin in wide variety of sample matrices. Microcystin analogues targeted were MC-LR, MC-RR, MC-LA, MC-LY, MC-LF, LC-LW, MC-YR, MC-WR, [Asp3] MC-LR, [Dha7] MC-LR, MC-HilR and MC-HtyR. Optimisation studies were conducted to develop a simple, quick and efficient extraction protocol without the need for complex pre-analysis concentration procedures, together with a rapid sub 5min chromatographic separation of toxins in shellfish and algal supplement tablet powders, as well as water and cyanobacterial bloom samples. Validation studies were undertaken on each matrix-analyte combination to the full method performance characteristics following international guidelines. The method was found to be specific and linear over the full calibration range. Method sensitivity in terms of limits of detection, quantitation and reporting were found to be significantly improved in comparison to LC-UV methods and applicable to the analysis of each of the four matrices. Overall, acceptable recoveries were determined for each of the matrices studied, with associated precision and within-laboratory reproducibility well within expected guidance limits. Results from the formalised ruggedness analysis of all available cyanotoxins, showed that the method was robust for all parameters investigated. The results presented here show that the optimised LC-MS/MS method for cyanotoxins is fit for the purpose of detection and quantitation of a range of microcystins and nodularin in shellfish, algal supplement tablet powder, water and cyanobacteria. The method provides a valuable early warning tool for the rapid, routine extraction and analysis of natural waters, cyanobacterial blooms, algal powders, food supplements and shellfish tissues, enabling monitoring labs to supplement traditional microscopy techniques and report toxicity results within a short timeframe of sample receipt. The new method, now accredited to ISO17025 standard, is simple, quick, applicable to multiple matrices and is highly suitable for use as a routine, high-throughout, fast turnaround regulatory monitoring tool.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Cianobactérias/química
Suplementos Nutricionais/análise
Microcistinas/análise
Peptídeos Cíclicos/análise
Frutos do Mar/análise
[Mh] Termos MeSH secundário: Animais
Produtos Biológicos/análise
Produtos Biológicos/química
Bivalves
Contaminação de Alimentos
Limite de Detecção
Modelos Lineares
Reprodutibilidade dos Testes
Comprimidos
Espectrometria de Massas em Tandem/métodos
Poluentes Químicos da Água/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Microcystins); 0 (Peptides, Cyclic); 0 (Tablets); 0 (Water Pollutants, Chemical); 0979BIK2QU (nodularin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  3 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29311542
[Au] Autor:Cao J; Perez-Pinera P; Lowenhaupt K; Wu MR; Purcell O; de la Fuente-Nunez C; Lu TK
[Ad] Endereço:Synthetic Biology Group, Department of Biological Engineering and Electrical Engineering & Computer Science, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
[Ti] Título:Versatile and on-demand biologics co-production in yeast.
[So] Source:Nat Commun;9(1):77, 2018 01 08.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Current limitations to on-demand drug manufacturing can be addressed by technologies that streamline manufacturing processes. Combining the production of two or more drugs into a single batch could not only be useful for research, clinical studies, and urgent therapies but also effective when combination therapies are needed or where resources are scarce. Here we propose strategies to concurrently produce multiple biologics from yeast in single batches by multiplexing strain development, cell culture, separation, and purification. We demonstrate proof-of-concept for three biologics co-production strategies: (i) inducible expression of multiple biologics and control over the ratio between biologic drugs produced together; (ii) consolidated bioprocessing; and (iii) co-expression and co-purification of a mixture of two monoclonal antibodies. We then use these basic strategies to produce drug mixtures as well as to separate drugs. These strategies offer a diverse array of options for on-demand, flexible, low-cost, and decentralized biomanufacturing applications without the need for specialized equipment.
[Mh] Termos MeSH primário: Produtos Biológicos/metabolismo
Preparações Farmacêuticas/metabolismo
Saccharomyces cerevisiae/metabolismo
Tecnologia Farmacêutica/métodos
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/biossíntese
Anticorpos Monoclonais/isolamento & purificação
Produtos Biológicos/isolamento & purificação
Análise Custo-Benefício
Seres Humanos
Preparações Farmacêuticas/isolamento & purificação
Saccharomyces cerevisiae/crescimento & desenvolvimento
Tecnologia Farmacêutica/economia
Tecnologia Farmacêutica/instrumentação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Biological Products); 0 (Pharmaceutical Preparations)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02587-w


  4 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29184405
[Au] Autor:Hureaux J; Lacoeuille F; Lagarce F; Rousselet MC; Contini A; Saulnier P; Benoit JP; Urban T
[Ad] Endereço:Unité Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire.
[Ti] Título:Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats.
[So] Source:Int J Nanomedicine;12:8159-8170, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Lipid nanocapsules (LNCs) are potential drug carriers for pulmonary delivery since they can be nebulized without any structural or functional changes, and the aerosols produced are highly compatible with pulmonary drug delivery in human beings. The alveolar surface tension, in vitro cytotoxicity, biodistribution and pulmonary toxicity in rats of a single endotracheal spray of LNCs or paclitaxel-loaded LNCs were studied. In vitro cytotoxicity of LNCs after a spray remained unchanged. Biodistribution study showed a homogeneous repartition in the lungs in rats with an improvement in lung retention of the radiolabeled tracer loaded in LNCs compared to the absence of LNCs with a lung half-time of 8.8±0.7 hours. Bronchoalveolar fluid analysis revealed transient 7-day alveolar inflammation, reaching a maximum between days 2 and 4, characterized by a peak of granulocytes at day 1 followed by a peak of lymphocytes at day 3. Alveolar protein levels were increased at days 3 and 7. Acute inflammation was increased with paclitaxel-loaded LNCs in comparison with blank LNCs but dropped out at day 7. No histological pulmonary lesion was observed at day 60. LNCs lowered surface tension to a greater degree than Curosurf in a physicochemical model of the pulmonary alveolus. A single pulmonary delivery of LNCs induces a short-term alveolar inflammation with no residual lesions in rats at day 60. These data permit to start the study of LNCs in surfactant replacement therapy.
[Mh] Termos MeSH primário: Portadores de Fármacos/efeitos adversos
Portadores de Fármacos/farmacocinética
Pulmão/efeitos dos fármacos
Pulmão/patologia
Nanocápsulas/efeitos adversos
[Mh] Termos MeSH secundário: Aerossóis/administração & dosagem
Aerossóis/efeitos adversos
Aerossóis/química
Animais
Produtos Biológicos
Linhagem Celular
Portadores de Fármacos/administração & dosagem
Sistemas de Liberação de Medicamentos/efeitos adversos
Sistemas de Liberação de Medicamentos/métodos
Feminino
Fibrose
Seres Humanos
Lipídeos/química
Nanocápsulas/administração & dosagem
Nanocápsulas/química
Paclitaxel/química
Paclitaxel/farmacocinética
Fosfolipídeos
Alvéolos Pulmonares/efeitos dos fármacos
Alvéolos Pulmonares/fisiopatologia
Ratos Sprague-Dawley
Tensão Superficial/efeitos dos fármacos
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Biological Products); 0 (Drug Carriers); 0 (Lipids); 0 (Nanocapsules); 0 (Phospholipids); KE3U2023NP (poractant alfa); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S146740


  5 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29353722
[Au] Autor:Xu GB; Xiao YH; Zhang QY; Zhou M; Liao SG
[Ad] Endereço:School of Pharmacy/State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550004, Guizhou, China; National Engineering Research Center of Miao's Medicines & Engineering Research Center for the Development and Application of Ethnic Medicine and
[Ti] Título:Hepatoprotective natural triterpenoids.
[So] Source:Eur J Med Chem;145:691-716, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Liver diseases are one of the leading causes of death in the world. In spite of tremendous advances in modern drug research, effective and safe hepatoprotective agents are still in urgent demand. Natural products are undoubtedly valuable sources for drug leads. A number of natural triterpenoids were reported to possess pronounced hepatoprotective effects, and triterpenoids have become one of the most important classes of natural products for hepatoprotective agents. However, the significance of natural triterpenoids has been underestimated in the hepatoprotective drug discovery, with only very limited triterpenoids being covered in the reviews of hepatoprotective natural products. In this paper, ca 350 natural triterpenoids with reported hepatoprotective effects in ca 120 references between 1975 and 2016 will be reviewed, and the structure-activity relationships of certain types of natural triterpenoids, if available, will be discussed. Patents are not included.
[Mh] Termos MeSH primário: Produtos Biológicos/farmacologia
Hepatopatias/tratamento farmacológico
Fígado/efeitos dos fármacos
Substâncias Protetoras/farmacologia
Triterpenos/farmacologia
[Mh] Termos MeSH secundário: Animais
Produtos Biológicos/química
Relação Dose-Resposta a Droga
Seres Humanos
Fígado/patologia
Estrutura Molecular
Substâncias Protetoras/química
Relação Estrutura-Atividade
Triterpenos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biological Products); 0 (Protective Agents); 0 (Triterpenes)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE


  6 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289883
[Au] Autor:Rejhová A; Opattová A; Cumová A; Slíva D; Vodicka P
[Ad] Endereço:Institute of Experimental Medicine of the Czech Academy of Sciences, Department of Molecular Biology of Cancer, Prague, 14220, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, 12800, Czech Republic. Electronic address: alexandra.rejhov
[Ti] Título:Natural compounds and combination therapy in colorectal cancer treatment.
[So] Source:Eur J Med Chem;144:582-594, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Colorectal cancer (CRC) therapy using conventional chemotherapeutics represents a considerable burden for the patient's organism because of high toxicity while the response is relatively low. Our review summarizes the findings about natural compounds as chemoprotective agents for decreasing risk of CRC. It also identifies natural compounds which possess anti-tumor effects of various characteristics, mainly in vitro on colorectal cell lines or in vivo studies on experimental models, but also in a few clinical trials. Many of natural compounds suppress proliferation by inducing cell cycle arrest or induce apoptosis of CRC cells resulting in the inhibition of tumor growth. A novel employment of natural substances is a so-called combination therapy - administration of two or more substances - conventional chemotherapeutics and a natural compound or more natural compounds at a time. Some natural compounds may sensitize to conventional cytotoxic therapy, reinforce the drug effective concentration, intensify the combined effect of both administered therapeutics or exert cytotoxic effects specifically on tumor cells. Moreover, combined therapy by targeting multiple signaling pathways, uses various mechanisms to reduce the development of resistance to antitumor drugs. The desired effect could be to diminish burden on the patient's organism by replacing part of the dose of a conventional chemotherapeutic with a natural substance with a defined effect. Many natural compounds are well tolerated by the patients and do not cause toxic effects even at high doses. Interaction of conventional chemotherapeutics with natural compounds introduces a new aspect in the research and therapy of cancer. It could be a promising approach to potentially achieve improvements, while minimizing of adverse effects associated with conventional chemotherapy.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia
Produtos Biológicos/farmacologia
Neoplasias Colorretais/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Protocolos de Quimioterapia Combinada Antineoplásica/química
Produtos Biológicos/química
Produtos Biológicos/isolamento & purificação
Proliferação Celular/efeitos dos fármacos
Neoplasias Colorretais/patologia
Relação Dose-Resposta a Droga
Seres Humanos
Estrutura Molecular
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biological Products)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  7 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29391009
[Au] Autor:Huang C; Li W; Zhang Q; Chen L; Chen W; Zhang H; Ni Y
[Ad] Endereço:Department of Pharmacy, Wuhan No.1 Hospital (Wuhan Integrated TCM & Western Medicine Hospital), 215 Zhongshan Avenue, Wuhan, 430022, China.
[Ti] Título:Anti-inflammatory activities of Guang-Pheretima extract in lipopolysaccharide-stimulated RAW 264.7 murine macrophages.
[So] Source:BMC Complement Altern Med;18(1):46, 2018 Feb 01.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Guang-Pheretima, which is originated from Pheretima aspergillum, has been documented in academic Chinese herbal studies for nearly 2000 years for its prominent treating effects of various inflammatory diseases such as asthma, cough and fever. However, the anti-inflammatory activity and mechanism of Guang-Pheretima has been rarely reported. Hence, we investigated the inhibitory effect and the underlying mechanism of Guang-Pheretima aqueous extracts on inflammatory response in RAW 264.7 cells. METHOD: RAW 264.7 macrophages were pretreated with various concentrations of Guang-Pheretima decoction (GPD) or protein-free Guang-Pheretima decoction (PF-GPD) and subsequently stimulated with lipopolysaccharide (LPS) to trigger the inflammatory response. Productions of nitric oxide (NO) were determined by Griess reaction, and prostaglandin E (PGE ), tumor necrosis factor-α (TNF-α), interleukin (IL)-1ß, IL-6 were measured by enzyme-linked immunosorbent assays (ELISA). The protein expressions and messenger ribonucleic acid (mRNA) amounts of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 were analyzed by Western Blot and Real-Time polymerase chain reaction (PCR), respectively. Finally, the translocation of nuclear factor (NF)-κB was observed by Western Blot. RESULTS: GPD of the experimental concentrations showed no anti-inflammatory activity. In contrast, PF-GPD at concentrations of 40-320 µg/mL significantly inhibited NF-κB activation and reduced the production of inflammatory mediators, such as NO, PGE , TNF-α, as well as the related key synthases including iNOS and COX-2. Moreover, PF-GPD markedly suppressed the release of inflammatory cytokines, such as IL-1ß and IL-6. CONCLUSION: These results demonstrate the excellent anti-inflammatory properties of PF-GPD, and suggest that Guang-Pheretima may be used to treat and prevent certain inflammatory diseases.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Produtos Biológicos/farmacologia
Macrófagos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/química
Produtos Biológicos/química
Sobrevivência Celular/efeitos dos fármacos
Ciclo-Oxigenase 2/metabolismo
Citocinas/análise
Citocinas/metabolismo
Lipopolissacarídeos/toxicidade
Macrófagos/metabolismo
Camundongos
Oligoquetos/química
Células RAW 264.7
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Biological Products); 0 (Cytokines); 0 (Lipopolysaccharides); EC 1.14.99.1 (Cyclooxygenase 2)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-018-2086-z


  8 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190135
[Au] Autor:Fonseca VA; Bloomgarden ZT; Dagogo-Jack S; Grunberger G; Einhorn D; Garber AJ; Handelsman Y; Hirsch IB; Umpierrez GE
[Ti] Título:AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.
[So] Source:Endocr Pract;23(11):1345-1349, 2017 Nov.
[Is] ISSN:1530-891X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. ABBREVIATIONS: BPCIA = Biologics Price Competition and Innovation Act; FDA = Food and Drug Administration; FFDC = Federal Food Drug and Cosmetics Act; PHS = Public Health Services Act; TE = therapeutic equivalence.
[Mh] Termos MeSH primário: Produtos Biológicos/uso terapêutico
Medicamentos Biossimilares/uso terapêutico
Doenças do Sistema Endócrino/tratamento farmacológico
[Mh] Termos MeSH secundário: Endocrinologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Biosimilar Pharmaceuticals)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.4158/EP-2017-0052


  9 / 16771 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29185959
[Au] Autor:Marchesoni A; Olivieri I; Salvarani C; Pipitone N; D'Angelo S; Mathieu A; Cauli A; Punzi L; Ramonda R; Scarpa R; Maccarone M; Lubrano E
[Ad] Endereço:Day Hospital of Rheumatology, ASST Gaetano Pini-CTO, Milano, Italy. antonio.marchesoni@asst-pini-cto.it.
[Ti] Título:Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.
[So] Source:Clin Exp Rheumatol;35(6):991-1010, 2017 Nov-Dec.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA). METHODS: To create this new set of recommendations, the SIR "Spondyloartritis and Psoriatic Arthritis study group - A. Spadaro" went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations. RESULTS: An update on the available evidence on all of the biologics and new small molecules tested in PsA is reported, comprising the data for each of the individual articular manifestation. Indications for therapy inclusion criteria, choice of the drug, disease assessment, response definition, therapy failure management, and disease remission management for PsA peripheral joint arthritis, enthesitis, dactylitis, and spondylitis are provided. Suggestions for the treatment of patients with PsA and concomitant extra-articular manifestations are also given. CONCLUSIONS: These evidence-based recommendations may be used for guidance in the complex and fast-evolving field of the treatment of PsA.
[Mh] Termos MeSH primário: Antirreumáticos/uso terapêutico
Artrite Psoriásica/tratamento farmacológico
Produtos Biológicos/uso terapêutico
[Mh] Termos MeSH secundário: Abatacepte/uso terapêutico
Anticorpos Monoclonais Humanizados/uso terapêutico
Prática Clínica Baseada em Evidências
Seres Humanos
Interleucina-17/antagonistas & inibidores
Guias de Prática Clínica como Assunto
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antirheumatic Agents); 0 (Biological Products); 0 (Interleukin-17); 0 (Tumor Necrosis Factor-alpha); 0 (clazakizumab); 7D0YB67S97 (Abatacept)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  10 / 16771 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386433
[Au] Autor:Hatakeyama S
[Ad] Endereço:Graduate School of Biomedical Sciences, Nagasaki University.
[Ti] Título:[Stereocontrolled Total Synthesis of Biologically Active Natural Products].
[So] Source:Yakugaku Zasshi;138(2):191-209, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: This review article describes the total syntheses of englerin A, ophiodilactones A and B, marinomycin A, N-methylwelwitindolinone C isothiocyanate, tirandamycins A-D, and tirandalydigin, which possess intriguing biological activities and challenging structures with characteristic ring systems. The focus is on the synthetic methodologies that lead to the highly stereocontrolled assembly of these natural products.
[Mh] Termos MeSH primário: Produtos Biológicos/síntese química
[Mh] Termos MeSH secundário: Alcenos/síntese química
Alcenos/química
Aminoglicosídeos/síntese química
Aminoglicosídeos/química
Derivados de Benzeno/síntese química
Derivados de Benzeno/química
Produtos Biológicos/química
Alcaloides de Indol/síntese química
Alcaloides de Indol/química
Lactonas/síntese química
Lactonas/química
Macrolídeos/síntese química
Macrolídeos/química
Conformação Molecular
Sesquiterpenos de Guaiano/síntese química
Sesquiterpenos de Guaiano/química
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alkenes); 0 (Aminoglycosides); 0 (Benzene Derivatives); 0 (Biological Products); 0 (Indole Alkaloids); 0 (Lactones); 0 (Macrolides); 0 (N-methylwelwitindolinone B isothiocyanate); 0 (Sesquiterpenes, Guaiane); 0 (englerin A); 0 (marinomycin A); 0 (ophiodilactone A); 0 (ophiodilactone B); 0 (tirandamycin C); 0 (tirandamycin D); 114118-91-1 (tirandalydigin); 34429-70-4 (tirandamycin A); 60587-14-6 (tirandamycin B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00187



página 1 de 1678 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde